JNJ Reports Nearly 3.5-Year Median Survival With RYBREVANT–LAZCLUZE in Atypical EGFR NSCLC — ASCO 2026 Update

Johnson & Johnson (JNJ) presented updated clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showing that patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations achieved a median overall survival of 41 months — roughly 3.5 years — when treated first-line with an intravenous combination of RYBREVANT and LAZCLUZE.

The results come from the Phase 1/1b CHRYSALIS-2 study. The updated analysis focuses on a first-line combination cohort of 49 patients whose tumors carried atypical EGFR alterations; more than one-third of those patients had multiple atypical mutations. Survival remained durable over time, with 55% of patients alive at three years and 46% alive at four years following initiation of the combination therapy.

CHRYSALIS-2 is an early-stage trial testing LAZCLUZE both as a single agent and in combination with RYBREVANT across a broader program that enrolled 460 patients. The updated findings reported at ASCO apply specifically to the 49-patient first-line atypical EGFR cohort and add to the evidence supporting further development of the combination in both common and atypical EGFR-mutated NSCLC.

“The responses we've seen in this trial suggest the potential for more durable disease control, and the overall survival data reinforce that picture,” said Joel Neal, the study's principal investigator and a professor of medicine at Stanford Medicine. He noted that treatment options for patients with atypical EGFR-mutated NSCLC remain limited and that long-term results like these could inform future care decisions for this subgroup.

Market reaction was mixed: JNJ shares fell about 2.3% during Friday afternoon trading despite the encouraging clinical update, although the stock has risen more than 47% over the past 12 months. Investor sentiment on social platforms such as Stocktwits moved to "bullish" from "neutral," with high message volume reported.

Context and Caveats

These data are promising but come from a small, early-phase cohort without a randomized comparator; larger, controlled studies will be necessary to confirm the survival benefit and to fully characterize safety and long-term outcomes. JNJ stated the results will inform ongoing development plans and discussions about treatment strategy for patients with atypical EGFR-mutated NSCLC.

For corrections or updates provided to the original outlet, contact newsroom[at]stocktwits[dot]com. The company and investigators plan to present detailed results and additional analyses as they become available.